TW202325728A - 治療阿茲海默症之方法 - Google Patents

治療阿茲海默症之方法 Download PDF

Info

Publication number
TW202325728A
TW202325728A TW111142020A TW111142020A TW202325728A TW 202325728 A TW202325728 A TW 202325728A TW 111142020 A TW111142020 A TW 111142020A TW 111142020 A TW111142020 A TW 111142020A TW 202325728 A TW202325728 A TW 202325728A
Authority
TW
Taiwan
Prior art keywords
tau
plasma
antibody
human subject
dose
Prior art date
Application number
TW111142020A
Other languages
English (en)
Chinese (zh)
Inventor
蘿拉 尼森鮑姆
陳天樂
拉傑 拉賈戈文丹
Original Assignee
美商渤健麻塞諸塞州股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商渤健麻塞諸塞州股份有限公司 filed Critical 美商渤健麻塞諸塞州股份有限公司
Publication of TW202325728A publication Critical patent/TW202325728A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
TW111142020A 2021-11-03 2022-11-03 治療阿茲海默症之方法 TW202325728A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163275442P 2021-11-03 2021-11-03
US63/275,442 2021-11-03
US202163277127P 2021-11-08 2021-11-08
US63/277,127 2021-11-08
US202263309796P 2022-02-14 2022-02-14
US63/309,796 2022-02-14
US202263343029P 2022-05-17 2022-05-17
US63/343,029 2022-05-17

Publications (1)

Publication Number Publication Date
TW202325728A true TW202325728A (zh) 2023-07-01

Family

ID=86241855

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142020A TW202325728A (zh) 2021-11-03 2022-11-03 治療阿茲海默症之方法

Country Status (5)

Country Link
US (1) US20240425573A1 (cg-RX-API-DMAC10.html)
EP (1) EP4426349A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024540294A (cg-RX-API-DMAC10.html)
TW (1) TW202325728A (cg-RX-API-DMAC10.html)
WO (1) WO2023081194A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240753A1 (en) * 2024-05-16 2025-11-20 Creative Bio-Peptides, Inc. Peptides and therapies for treating neurological disorders
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) * 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
WO2011133919A1 (en) * 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Use of tau to monitor immunotherapy
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
EP2885010B1 (en) * 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
WO2021016466A1 (en) * 2019-07-24 2021-01-28 Duke University Compositions and methods for the diagnosis and treatment of alzheimer's disease
CN114599393A (zh) * 2019-10-22 2022-06-07 比奥根Ma公司 治疗阿尔茨海默病的抗β-淀粉样蛋白抗体

Also Published As

Publication number Publication date
EP4426349A2 (en) 2024-09-11
WO2023081194A3 (en) 2023-10-26
WO2023081194A2 (en) 2023-05-11
US20240425573A1 (en) 2024-12-26
EP4426349A4 (en) 2025-10-29
JP2024540294A (ja) 2024-10-31

Similar Documents

Publication Publication Date Title
US20220281963A1 (en) Methods for treating alzheimer's disease
US20220372123A1 (en) Anti-beta-amyloid antibody for treating alzheimer's disease
JP2020055880A (ja) アルツハイマー病の治療法
TW202317192A (zh) 用於阿茲海默氏症治療的生物標記物
US20240425573A1 (en) Methods for treating alzheimer's disease
KR20250114372A (ko) 타우(tau) pet 수준을 이용하는 치료 방법
TW202334201A (zh) 抗Tau抗體之組成物、劑型及方法
KR20240142535A (ko) P-tau181 수준을 사용한 치료 방법
CN120583962A (zh) 抗N3pGluβ淀粉样蛋白抗体、其剂量及其用途
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
CN120826223A (zh) 鲨肌醇与免疫治疗剂组合用于治疗阿尔茨海默氏病
US20240270830A1 (en) Methods for treating alzheimer's disease
CN118829445A (zh) 用于治疗阿尔茨海默病的方法
WO2025240435A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
WO2026057816A1 (en) Treatment of tauopathies with tau-binding antibodies
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
NZ788486A (en) Methods for treating Alzheimer's disease